Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Atherosclerosis ; 384: 117117, 2023 11.
Article in English | MEDLINE | ID: mdl-37080805

ABSTRACT

BACKGROUND AND AIMS: Despite lipid lowering therapy (LLT), reaching LDL-C targets in patients with familial hypercholesterolemia (FH) remains challenging. Our aim was to determine attainment of LDL-C target levels and reasons for not reaching these in female and male FH patients. METHODS: We performed a cross-sectional study of heterozygous FH patients in five hospitals in the Netherlands and Norway. Clinical characteristics and information about LLT, lipid levels and reasons for not being on LDL-C treatment target were retrospectively collected from electronic medical records. RESULTS: We studied 3178 FH patients (53.9% women), median age 48.0 (IQR 34.0-59.9) years. Median LDL-C before treatment and on-treatment was higher in women compared to men (6.2 (IQR 5.1-7.3) and 6.0 (IQR 4.9-7.2) mmol/l (p=0.005) and 3.0 (IQR 2.4-3.8) and 2.8 (IQR 2.3-3.5) mmol/L (p<0.001)), respectively. A minority of women (26.9%) and men (28.9%) reached LDL-C target. In patients with CVD, 17.2% of women and 25.8% of men reached LDL-C target. Women received less often high-intensity statins and ezetimibe. Most common reported reasons for not achieving the LDL-C target were insufficient effect of maximum LLT (women 17.3%, men 24.3%) and side effects (women 15.2%, men 8.6%). CONCLUSIONS: In routine practice, only a minority of women and men with FH achieved their LDL-C treatment target. Extra efforts have to be made to provide FH patients with reliable information on the safety of statins and their long-term effects on CVD risk reduction. If statin treatment is insufficient, alternative lipid lowering therapies such as ezetimibe or PCSK9-inhibitors should be considered.


Subject(s)
Anticholesteremic Agents , Cardiovascular Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hyperlipoproteinemia Type II , Humans , Female , Male , Middle Aged , Cholesterol, LDL , Proprotein Convertase 9 , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Anticholesteremic Agents/adverse effects , Retrospective Studies , Cross-Sectional Studies , Treatment Outcome , Cardiovascular Diseases/drug therapy , Hyperlipoproteinemia Type II/diagnosis , Hyperlipoproteinemia Type II/drug therapy , Hyperlipoproteinemia Type II/genetics , Ezetimibe/therapeutic use
2.
Br J Pharmacol ; 171(3): 567-79, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23802760

ABSTRACT

Pulmonary arterial hypertension (PAH) is a complex disease characterized by elevated pulmonary arterial pressure, pulmonary vascular remodelling and occlusive pulmonary vascular lesions, leading to right heart failure. Evidence from recent epidemiological studies suggests the influence of gender on the development of PAH with an approximate female to male ratio of 4:1, depending on the underlying disease pathology. Overall, the therapeutic strategy for PAH remains suboptimal with poor survival rates observed in both genders. Endogenous sex hormones, in particular 17ß oestradiol and its metabolites, have been implicated in the development of the disease; however, the influence of sex hormones on the underlying pathobiology remains controversial. Further understanding of the influence of sex hormones on the normal and diseased pulmonary circulation will be critical to our understanding the pathology of PAH and future therapeutic strategies. In this review, we will discuss the influence of sex hormones on the development of PAH and address recent controversies.


Subject(s)
Cardiovascular Agents/therapeutic use , Evidence-Based Medicine , Hypertension, Pulmonary/drug therapy , Lung/drug effects , Models, Biological , Pulmonary Circulation/drug effects , Androgens/metabolism , Animals , Disease Susceptibility , Drug Resistance , Estrogens/metabolism , Familial Primary Pulmonary Hypertension , Female , Humans , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/therapy , Incidence , Lung/blood supply , Lung/metabolism , Male , Receptors, Estrogen/metabolism , Sex Characteristics , Vascular Resistance/drug effects
3.
J Cell Physiol ; 177(1): 85-93, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9731748

ABSTRACT

Activation of the cAMP signaling pathway in lymphoid cells is known to inhibit cell proliferation of T and B cells as well as cytotoxicity of natural killer (NK) cells. In order to find suitable model systems to study cAMP-mediated processes, we have examined the expression of cAMP-dependent protein kinase (PKA), endogenous levels of cAMP, and cell proliferation in eight cell lines of B lineage origin, four cell lines of T lineage origin, and normal human B and T cells. We demonstrated that the expression of mRNA and protein for one of the regulatory (R) subunits of PKA (RIalpha) was present in all the cells investigated, in contrast to the other R subunits (RIbeta, RIIalpha, and RIIbeta). Furthermore, three T cell lines and one B cell line expressed only RIalpha and C, implying these cells to contain solely PKA type I. Moreover, for the RI subunit, we observed an apparent reciprocal relationship between levels of mRNA and protein. Generally, RIalpha protein was low in cell lines where mRNA was elevated and vice versa. This was not the case for the RII subunits, where high levels of mRNA were associated with elevated levels of protein. Interestingly, we demonstrated an inverse correlation between levels of endogenous cAMP and cell growth as determined by [3H]-thymidine incorporation and cell-doubling rate (P < 0.05). Taken together, our results demonstrate great differences in PKA isozyme composition, which should be taken into consideration when using lymphoid cell lines as model system for cAMP/PKA effects in normal lymphocytes.


Subject(s)
B-Lymphocytes/cytology , Cyclic AMP-Dependent Protein Kinases/genetics , Cyclic AMP/metabolism , Gene Expression Regulation, Enzymologic , Isoenzymes/genetics , T-Lymphocytes/cytology , B-Lymphocytes/enzymology , Blotting, Northern , Blotting, Western , Burkitt Lymphoma , Cell Division/physiology , Cyclic AMP-Dependent Protein Kinases/analysis , Gene Expression Regulation, Neoplastic , Humans , Isoenzymes/analysis , Jurkat Cells/cytology , Jurkat Cells/enzymology , Lymphoma, Non-Hodgkin , Multiple Myeloma , Precursor Cell Lymphoblastic Leukemia-Lymphoma , RNA, Messenger/analysis , T-Lymphocytes/enzymology , Tritium
4.
Article in English | MEDLINE | ID: mdl-9344252

ABSTRACT

A large number of hormones, neurotransmitters, and other signaling substances that bind to G-protein-coupled cell-surface receptors have their signals converge at one sole second messenger, cAMP. The question of how specificity can be maintained in a signal-transduction system in which many extracellular signals leading to a vast array of intracellular responses are all mediated through one second-messenger system has been the subject of thorough investigation and a great deal of speculation. An increasing number of cAK isozymes, consisting of homo- or heterodimers of R subunits (RIalpha, RIbeta, RIIalpha, RIIbeta) with associated catalytic subunits (C alpha, Cbeta, Cgamma), may, at least in part, explain this specificity. The various cAK isozymes display distinct biochemical properties, and the heterogeneous subunits of cAK reveal cell-specific expression and differential regulation at the level of gene transcription, mRNA stability, and protein stability in response to a wide range of hormones and other signaling substances. The existence of a number of anchoring proteins specific to either RIIalpha or RIIbeta, and which localize cAKII isozymes toward distinct substrates at defined subcellular loci, strongly supports the idea that specific functions can be assigned to the various cAK isozymes. The demonstration that selective activation of cAKI is necessary and sufficient for cAMP-mediated inhibition of T-cell proliferation, and the observation that T-cell activation is associated with redistribution and colocalization of cAKI to the TCR, is also compatible with the notion of isozyme-specific effects.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/chemistry , Cyclic AMP-Dependent Protein Kinases/physiology , Cloning, Molecular , Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit , Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit , Cyclic AMP-Dependent Protein Kinase RIalpha Subunit , Cyclic AMP-Dependent Protein Kinase RIbeta Subunit , Cyclic AMP-Dependent Protein Kinases/genetics , Humans , Isoenzymes/chemistry , Isoenzymes/genetics , Isoenzymes/physiology , Lymphocyte Activation , Protein Conformation , Signal Transduction , Subcellular Fractions/enzymology , T-Lymphocytes/enzymology , T-Lymphocytes/immunology , Tissue Distribution
5.
Biochem Pharmacol ; 43(4): 725-9, 1992 Feb 18.
Article in English | MEDLINE | ID: mdl-1540225

ABSTRACT

The present study shows that ANS (1-anilino-8-naphthalene sulfonate), propranolol, isoprenaline, adrenaline and dopamine have common binding sites on AAG (alpha 1-acid glycoprotein). A fluorescence technique was employed to characterize the interaction between the ligands and AAG at 20-22 degrees. The binding of ANS to AAG caused increased fluorescence intensity at emission and excitation wavelengths of 400 and 470 nm. In this situation, propranolol displaced ANS in a concentration-dependent mode with an apparent dissociation constant of 6.2 +/- 0.01 microM, whereas isoprenaline did not reduce the ANS-AAG fluorescence. However, in the presence of AAG, catecholamines caused a marked increase of fluorescence at excitation and emission wavelengths of 250 and 325 nm, respectively. These wavelengths were employed to characterize the binding of isoprenaline, adrenaline and propranolol to AAG. Two subsets of binding sites were demonstrated. The Kd values were 0.87 +/- 0.03 and 25.1 +/- 10.7 microM for ANS, 0.76 +/- 0.09 and 133 +/- 30.4 microM for propranolol, 140 +/- 14 and 2.18 +/- 0.58 mM for isoprenaline, 137 +/- 24 and 14.8 +/- 0.1 mM for adrenaline, respectively. AAG had identical high affinity binding capacity for these ligands (n approximately 1). However, the second class of binding sites showed ligand-dependent binding capacity: n = 1 for ANS, n approximately 10 for propranolol, n approximately 15 for adrenaline, n approximately 20 for isoprenaline, respectively. ANS, propranolol, dopamine and adrenaline caused concentration-dependent inhibition of isoprenaline binding to AAG with apparent dissociation constants of 5.1 +/- 1.8 microM, 6.4 +/- 1.1 microM, 0.57 +/- 0.13 mM and 1.5 +/- 0.46 mM, respectively.


Subject(s)
Anilino Naphthalenesulfonates , Epinephrine/metabolism , Isoproterenol/metabolism , Orosomucoid/metabolism , Propranolol/metabolism , Ascorbic Acid/chemistry , Binding Sites , Dopamine/chemistry , Dose-Response Relationship, Drug , Epinephrine/chemistry , Humans , Isoproterenol/chemistry , Orosomucoid/chemistry , Orosomucoid/isolation & purification , Propranolol/chemistry , Spectrometry, Fluorescence
6.
Acta Vet Scand ; 33(4): 297-303, 1992.
Article in English | MEDLINE | ID: mdl-1488945

ABSTRACT

The spread of lactic acid bacterial strains to the environment and to newborn piglets was investigated after feeding of such strains to sows. Rifampicin resistant bacterial strains were fed to sows, 10(10) c.f.u. per day, during the period from 1 week before expected farrowing until 1 week after farrowing. Fecal samples from the sows and samples of litter were collected for bacteriological examination together with swabs from the pens, the skin of the sows, and from the rectum of the piglets. The test strains were only excreted in relatively low amounts in the feces of the sows, approximately 10(3)-10(6) c.f.u. per gram. They were not able to displace the normal lactic acid bacterial flora in the sows nor were they transmitted to the intestinal tract of the piglets to any significant extent. After the last administration the test strains disappeared from both feces, skin, and environment, indicating that no permanent colonization had taken place, although considerable differences in duration of persistence were noticed between test strains.


Subject(s)
Intestines/microbiology , Lactobacillus/growth & development , Swine/microbiology , Animal Feed/microbiology , Animals , Bacterial Infections/transmission , Bacterial Infections/veterinary , Environmental Microbiology , Feces/microbiology , Female , Swine Diseases/microbiology , Swine Diseases/transmission
SELECTION OF CITATIONS
SEARCH DETAIL
...